Follistatin-a circulating biomarker for type 2 diabetes

被引：0
|
作者：
Wu, C. [1 ]
Borne, Y. [1 ]
Rodriguez, M. Lopez [2 ]
Duffin, K. L. [3 ]
Gao, R. [4 ]
Melander, O. [1 ]
Melander, M. Orho [1 ]
Shore, A. [5 ]
Khan, F. [6 ]
Natali, A. [7 ]
Nilsson, J. [1 ]
Vaag, A. [8 ]
Laakso, M. [2 ]
Groop, L. [1 ]
De Marinis, Y. [1 ]
机构：
[1] Lund Univ, Malmo, Sweden
[2] Univ Eastern Finland, Kuopio, Finland
[3] Lilly Res Labs, Indianapolis, IN USA
[4] Shandong Univ, Jinan, Shandong, Peoples R China
[5] NIHR Exeter Clin Res Facil, Exeter, Devon, England
[6] Ctr Cardiovasc & Lung Biol, Vasc & Inflammatory Dis Res Unit, Dundee, Scotland
[7] Univ Pisa, Sch Med, Expt & Clin Med, Pisa, Italy
[8] AstraZeneca, IMEDIMED Biotech Unit, Gothenburg, Sweden
来源：
DIABETOLOGIA | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
172
引用
收藏
页码：S88 / S88
页数：1
相关论文
共 50 条
  • [1] Circulating follistatin as a novel biomarker of type 2 diabetes mellitus risk
    Stella Papachristou
    Djordje S. Popovic
    Nikolaos Papanas
    International Journal of Diabetes in Developing Countries, 2023, 43 : 779 - 780
  • [2] Circulating follistatin as a novel biomarker of type 2 diabetes mellitus risk
    Papachristou, Stella
    Popovic, Djordje S.
    Papanas, Nikolaos
    INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2023, 43 (05) : 779 - 780
  • [3] Elevated circulating follistatin associates with an increased risk of type 2 diabetes
    Chuanyan Wu
    Yan Borné
    Rui Gao
    Maykel López Rodriguez
    William C. Roell
    Jonathan M. Wilson
    Ajit Regmi
    Cheng Luan
    Dina Mansour Aly
    Andreas Peter
    Jürgen Machann
    Harald Staiger
    Andreas Fritsche
    Andreas L. Birkenfeld
    Rongya Tao
    Robert Wagner
    Mickaël Canouil
    Mun-Gwan Hong
    Jochen M. Schwenk
    Emma Ahlqvist
    Minna U. Kaikkonen
    Peter Nilsson
    Angela C. Shore
    Faisel Khan
    Andrea Natali
    Olle Melander
    Marju Orho-Melander
    Jan Nilsson
    Hans-Ulrich Häring
    Erik Renström
    Claes B. Wollheim
    Gunnar Engström
    Jianping Weng
    Ewan R. Pearson
    Paul W. Franks
    Morris F. White
    Kevin L. Duffin
    Allan Arthur Vaag
    Markku Laakso
    Norbert Stefan
    Leif Groop
    Yang De Marinis
    Nature Communications, 12
  • [4] Circulating Follistatin and Activin A and Their Regulation by Insulin in Obesity and Type 2 Diabetes
    Sylow, Lykke
    Vind, Birgitte F.
    Kruse, Rikke
    Moller, Pauline M.
    Wojtaszewski, Jorgen F. P.
    Richter, Erik A.
    Hojlund, Kurt
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (05):
  • [5] Circulating Follistatin Predicts Tirzepatide Treatment Outcomes on Type 2 Diabetes
    Zou, Qi
    Engstrom, Gunnar
    Pan, Jingxue
    Zhang, Jialin
    Perisho, Esther J.
    Lin, Yanzhu
    Wiese, Russell
    Wilson, Jonathan M.
    Pavo, Imre
    Gao, Rui
    Duffin, Kevin L.
    De Marinis, Yang
    DIABETES, 2024, 73
  • [6] Elevated circulating follistatin associates with an increased risk of type 2 diabetes
    Wu, Chuanyan
    Borne, Yan
    Gao, Rui
    Rodriguez, Maykel Lopez
    Roell, William C.
    Wilson, Jonathan M.
    Regmi, Ajit
    Luan, Cheng
    Aly, Dina Mansour
    Peter, Andreas
    Machann, Juergen
    Staiger, Harald
    Fritsche, Andreas
    Birkenfeld, Andreas L.
    Tao, Rongya
    Wagner, Robert
    Canouil, Mickael
    Hong, Mun-Gwan
    Schwenk, Jochen M.
    Ahlqvist, Emma
    Kaikkonen, Minna U.
    Nilsson, Peter
    Shore, Angela C.
    Khan, Faisel
    Natali, Andrea
    Melander, Olle
    Orho-Melander, Marju
    Nilsson, Jan
    Haering, Hans-Ulrich
    Renstrom, Erik
    Wollheim, Claes B.
    Engstrom, Gunnar
    Weng, Jianping
    Pearson, Ewan R.
    Franks, Paul W.
    White, Morris F.
    Duffin, Kevin L.
    Vaag, Allan Arthur
    Laakso, Markku
    Stefan, Norbert
    Groop, Leif
    De Marinis, Yang
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [7] Follistatin linked to type 2 diabetes mellitus risk
    Tysoe O.
    Nature Reviews Endocrinology, 2022, 18 (2) : 69 - 69
  • [8] Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes
    Fujisawa, Keiko
    Katakami, Naoto
    Kaneto, Hideaki
    Naka, Toyoko
    Takahara, Mitsuyoshi
    Sakamoto, Fumie
    Irie, Yoko
    Miyashita, Kazuyuki
    Kubo, Fumiyo
    Yasuda, Tetsuyuki
    Matsuoka, Taka-aki
    Shimomura, Iichiro
    ATHEROSCLEROSIS, 2013, 227 (02) : 425 - 428
  • [9] A High Level of Circulating Valine Is a Biomarker for Type 2 Diabetes and Associated with the Hypoglycemic Effect of Sitagliptin
    Liao, Xiaoyu
    Liu, Bingyao
    Qu, Hua
    Zhang, LinLin
    Lu, Yongling
    Xu, Yong
    Lyu, Zhaohui
    Zheng, Hongting
    MEDIATORS OF INFLAMMATION, 2019, 2019
  • [10] Altered follistatin secretion profile during exercise in type 2 diabetes
    Hansen, J.
    Pedersen, B.
    Plomgaard, P.
    DIABETOLOGIA, 2013, 56 : S278 - S279
12345